News
News
Date Title
   
January 11, 2012 Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
September 13, 2011 Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer
September 9, 2011 CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics
September 2, 2011 Oxford BioTherapeutics licenses Lonza’s GS Gene Expression System™
April 6, 2011 Oxford BioTherapeutics Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
January 25, 2011 Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers
December 09, 2009 Oxford BioTherapeutics Appoints Michael Moore as Chairman
November 11, 2009 Oxford BioTherapeutics Recruits mAb Industry Leaders to Head US Operations
May 18, 2009 Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
December 1, 2008 Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics
February 18, 2008 Oxford Genome Sciences Appoints Professor Elke Jaeger to its Scientific Advisory Board
December 17, 2007 Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
November 21, 2007 Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors
October 11, 2007 Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board
September 18, 2007 Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex
April 18, 2007 Oxford Genome Sciences Recruits Senior Industry Professionals to Drive its Development of Novel Personalised Medicines
March 5, 2007 Oxford Genome Sciences Expands its Scientific Advisory Board
Feb 5, 2007 Oxford Genome Sciences (UK) Ltd secured additional private equity investment round
View All Press Releases
 
| Home | About Us | Collaborations | Technologies | News/Events | Contact Us |
© Oxford BioTherapeutics Ltd 2009. All rights reserved.